title: Rosiglitazone and the FDA.
authors.forename: Hylton V
authors.initials: HV
authors.lastname: Joffe
authors.forename: Mary H
authors.initials: MH
authors.lastname: Parks
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Meyer
authors.forename: John K
authors.initials: JK
authors.lastname: Jenkins
authors.forename: Robert
authors.initials: R
authors.lastname: Temple
mesh_terms: D026683:Advisory Committees; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D017277:Drug Approval; D006442:Glycated Hemoglobin; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000077154:Rosiglitazone; D045162:Thiazolidinediones